RxDoctor Payments Data

Uchenna Kalu, MD

Internal Medicine · Decatur, GANPI 1841312907

Payments from drug & device makers

$5,116in general payments, 2019–2025

Across 52 payments — averaging $98.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • Lilly USA, LLC$300
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$179
  • Acadia Pharmaceuticals Inc$151
  • Exact Sciences$110
  • UCB, Inc.$85
  • plus $267 from 9 others

What the payments were for

  • Consulting fees$2,50049%
  • Travel & lodging$1,33326%
  • Food & beverage$1,28325%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,116 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$75,387
Medicare patients
146
Services billed
773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban476$206,077
OzempicSemaglutide49$65,251
MounjaroTirzepatide40$62,738
JanuviaSitagliptin Phosphate53$48,132
TrulicityDulaglutide51$44,656
XareltoRivaroxaban95$44,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$37,110
EntrestoSacubitril/Valsartan51$34,304
JardianceEmpagliflozin47$34,130
RenvelaSevelamer Carbonate22$22,509
GemtesaVibegron21$18,240
FarxigaDapagliflozin Propanediol33$17,883
LinzessLinaclotide17$14,831
VeltassaPatiromer Calcium Sorbitex13$12,925
Spiriva HandihalerTiotropium Bromide16$10,967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$300$107,39491 claims
Novo NordiskOzempic$23$65,25149 claims
Johnson & JohnsonXarelto$12$44,39995 claims
Boehringer IngelheimJardiance, Tradjenta$18$40,42971 claims
NovartisEntresto$18$34,30451 claims
AstraZenecaFarxiga$47$17,88333 claims
Astellas Pharma US IncMyrbetriq$27$8,82433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →